Bank of America Lowers Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00

Y-mAbs Therapeutics (NASDAQ:YMAB) had its target price decreased by Bank of America from $14.00 to $12.00 in a research note published on Wednesday morning,Benzinga reports. Bank of America currently has a neutral rating on the stock.

Several other research analysts have also recently commented on YMAB. HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Brookline Capital Management started coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 target price on the stock. Morgan Stanley lowered their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday. Wedbush reaffirmed an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Monday. Finally, Oppenheimer started coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Y-mAbs Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $19.30.

Y-mAbs Therapeutics Stock Down 2.2 %

Shares of YMAB stock opened at $4.85 on Wednesday. The firm has a 50 day moving average price of $6.46 and a two-hundred day moving average price of $10.62. The company has a market capitalization of $217.23 million, a PE ratio of -8.98 and a beta of 0.65. Y-mAbs Therapeutics has a 12-month low of $4.25 and a 12-month high of $18.19.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. During the same quarter last year, the business earned ($0.02) earnings per share. As a group, research analysts expect that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in YMAB. Acorn Capital Advisors LLC bought a new stake in shares of Y-mAbs Therapeutics during the fourth quarter worth $22,408,000. Caligan Partners LP grew its stake in shares of Y-mAbs Therapeutics by 105.3% during the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after buying an additional 613,175 shares during the last quarter. State Street Corp grew its stake in shares of Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after buying an additional 405,169 shares during the last quarter. Infinitum Asset Management LLC bought a new stake in shares of Y-mAbs Therapeutics during the fourth quarter worth $1,218,000. Finally, Paradigm Biocapital Advisors LP grew its stake in shares of Y-mAbs Therapeutics by 3.7% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company’s stock worth $33,171,000 after buying an additional 150,000 shares during the last quarter. 70.85% of the stock is owned by institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.